XML 34 R76.htm IDEA: XBRL DOCUMENT v2.4.1.9
Discontinued Operations (Details) (USD $)
12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Regenerative Medicine - China segment [Member]    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Disposal Group, Including Discontinued Operation, Revenue $ 52,300us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_RegenerativeMedicineChinaSegmentMember
 
Disposal Group, Including Discontinued Operation, Costs of Goods Sold 30,600us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_RegenerativeMedicineChinaSegmentMember
 
Disposal Group Including Discontinued Operation Research and Development 103,300nbs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_RegenerativeMedicineChinaSegmentMember
 
Disposal Group Including Discontinued Operation Selling General and Administrative 497,300nbs_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrative
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_RegenerativeMedicineChinaSegmentMember
 
Disposal Group, Including Discontinued Operation, Operating Expense 6,800us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_RegenerativeMedicineChinaSegmentMember
 
Loss on Exit of Segment 1,138,000nbs_LossOnExitOfSegment
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_RegenerativeMedicineChinaSegmentMember
 
Pharmaceutical Manufacturing - China business [Member]    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Disposal Group, Including Discontinued Operation, Revenue 61,703,100us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents   8,457,500us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
Disposal Group, Including Discontinued Operation, Costs of Goods Sold 40,245,200us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Disposal Group Including Discontinued Operation Research and Development 1,836,400nbs_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Disposal Group Including Discontinued Operation Selling General and Administrative 10,740,000nbs_DisposalGroupIncludingDiscontinuedOperationSellingGeneralAndAdministrative
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember
 
Disposal Group, Including Discontinued Operation, Operating Expense $ 1,045,200us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense
/ us-gaap_StatementBusinessSegmentsAxis
= nbs_PharmaceuticalManufacturingChinaBusinessMember